n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
US$ 223 million will add biologics capacity to AbbVie’s production network
Singapore production will have more than 500 workers after expansion
Construction will begin and amenities will be operational in 2026.
SINGAPORE, Jan. 26, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie’s global network.
Located in Singapore’s Tuas Biomedical Park, AbbVie’s Singapore plant is a state-of-the-art small-molecule and biologics manufacturing facility serving markets worldwide. This new investment will add 24,000 liters of biologics drug-substance capacity to AbbVie’s global manufacturing network and support current products as well as emerging immunology and oncology compounds within AbbVie’s pipeline.
“This expansion announcement represents one of AbbVie’s many investments in its Singapore-based operations and the proud continuation of our decade-long partnership with the Government of Singapore,” said Azita Saleki-Gerhardt, Ph.D., AbbVie Executive Vice President, Chief Operations Officer. “The expansion of our Singapore site will strengthen our global manufacturing capabilities, support our growing biologics pipeline and help AbbVie continue delivering on our patient commitments now and in the future.”
With today’s announcement, AbbVie has invested more than US$740 million (S$1 billion) in the acquisition, enhancement and expansion of its services in Singapore over the past 10 years. When fully operational, the expanded production facility in Singapore – AbbVie’s only production in Asia – will employ more than 500 people in production, quality control, supply chain, engineering and management.
“We are very pleased that AbbVie has decided to expand its biologics production capacity in Singapore for existing and cutting-edge medicines in the long term. We are grateful for AbbVie’s continued confidence in the strength of Singapore’s biopharmaceutical manufacturing functions and skills base. AbbVie’s investment will go into Singapore’s complex, leading manufacturing ecosystem. and create exciting employment opportunities here,” said Cindy Koh, executive vice-president of the Singapore Economic Development Board.
Construction of the expansion will begin later this year and operations are expected to begin in 2026. AbbVie’s production facility in Singapore is part of AbbVie’s operations team, which has 14,000 workers at more than 30 production, operations and logistics locations across the United States. , Asia, Europe, Puerto Rico and South America.
About AbbVie
AbbVie’s vision is to detect and deliver cutting-edge medicines and responses that resolve serious fitness disorders today and address the demanding medical situations of tomorrow. We seek to make a notable impact on people’s lives in several key healing spaces (immunology, oncology, neuroscience and ophthalmic care), as well as across all products and facilities in our Allergan Aesthetics portfolio. For more information about AbbVie, visit us at www. abbvie. com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.
Media Contacts
John Torrisi, director
+1 (224) 213-0055
Yoosook Kim, director
+82 (02) 3429 9296
Yoosook. Kim@abbvie. com
See content to download multimedia: https://www. prnewswire. com/apac/news-releases/abbvie-expands-biologics-manufacturing-capacity-with-a-223-million-investment-in-singapore-manufacturing-site -302044676. html
SOURCE AbbVie